Market Place
Sourcing Support
Geron to Present RYTELO™ Data at ASH in Hematologic Malignancies
05 Nov 2024 //
BUSINESSWIRE
Geron Corporation Reports Q2 2024 Results And Business Highlights
08 Aug 2024 //
BUSINESSWIRE
NCCN Guidelines Now Include Geron`s RYTELO For Lower-Risk MDS Treatment
26 Jul 2024 //
BUSINESSWIRE
Onco360 Selected As Limited Distribution Partner For Rytelo
16 Jul 2024 //
GLOBENEWSWIRE
Onco360 Named Limited Distribution Partner For Rytelo™ (Imetelstat)
12 Jul 2024 //
GLOBENEWSWIRE
FDA signs off on Geron`s long-awaited blood cancer drug Rytelo
08 Jun 2024 //
FIERCE PHARMA
Geron`s RYTELO™ Telomerase Inhibitor Approved For Lower-Risk MDS
07 Jun 2024 //
BUSINESSWIRE
FDA Telomerase Approval Shows Viability Of MAIA`s Telomere Approach
07 Jun 2024 //
BUSINESSWIRE
Geron Announces FDA Approval Of RYTELO™ For Treatment Of Lower-Risk MDS
06 Jun 2024 //
BUSINESSWIRE
Geron`s blood disorder drug gets FDA advisers` backing
15 Mar 2024 //
YAHOO FINANCE
US FDA staff raises concerns on Geron`s blood disorder drug
13 Mar 2024 //
REUTERS
Geron Announces 50% Enrollment in the Phase 3 Trial Evaluating Imetelstat
06 Dec 2023 //
BUSINESSWIRE
Geron Announces Publication of Results from Phase 3 Evaluating Imetelstat
04 Dec 2023 //
BUSINESSWIRE
Geron IMerge Phase 3 Presentations Reinforce Durability of Imetelstat
02 Nov 2023 //
BUSINESSWIRE
Geron Announces EMA Validation of MAA for Imetelstat
29 Sep 2023 //
BUSINESSWIRE
Geron Announces Data Presentations from IMerge Phase 3 Evaluating Imetelstat
07 Sep 2023 //
BUSINESSWIRE
Geron Announces FDA Acceptance of New Drug Application for Imetelstat
21 Aug 2023 //
BUSINESSWIRE
FDA Accepts NDA for Imetelstat in Lower-Risk MDS
21 Aug 2023 //
ONCLIVE
Geron Announces First Patient Dosed in PII IMpress Trial Evaluating Imetelstat
13 Jun 2023 //
BUSINESSWIRE
Geron Announces Leadership Hired for Planned Commercial Launch of Imetelstat
11 Jan 2023 //
BUSINESSWIRE
Geron sells stock to raise over $200M after PhIII readout on MDS drug
11 Jan 2023 //
ENDPTS
Geron Announces PositiveResults from IMerge Phase 3 Trial of Imetelstat
04 Jan 2023 //
BUSINESSWIRE
Geron Announces Conference Call for Top-Line Results from IMerge Phase 3
03 Jan 2023 //
BUSINESSWIRE
Geron Corp Reports Q4 and Full Year 2021 Financial Results; Upcoming Milestones
10 Mar 2022 //
BUSINESSWIRE
Geron Enters New Innovative Licensing and Access Pathway in UK for Imetelstat
26 Oct 2021 //
BUSINESSWIRE
Geron Reports 2 Presentations at Virtual EHA Annual Congress
14 Jun 2021 //
BUSINESSWIRE
Geron Announces Ten Imetelstat Presentations at Upcoming American
04 Nov 2020 //
BUSINESSWIRE
Geron Reports Four Imetelstat Data Presentations at Virtual Edition of the (EHA)
12 Jun 2020 //
GLOBENEWSWIRE
Shares of biotech firm Geron fall 70% after Johnson & Johnson ends collaboration
27 Sep 2018 //
CNBC
J&J has cancelled deal on Geron’s imetelstat
27 Sep 2018 //
ENDPTS
Geron Announces Discontinuation of Imetelstat Collaboration by Janssen
27 Sep 2018 //
GLOBENEWSWIRE
